Tumor mutational burden (TMB) can function as a biomarker for response to immunotherapy. Understanding how to accurately test TMB and understanding the implications of variation in the results can inform treatment. This study, published in Clinical Research (Excluding Clinical Trials), analyzed the genomic profiles of patients with cancer to assess TMB prevalence and variability, and its...